Dundee - UK - 4 November 2014 – Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow (SLF) technology to replicate natural blood flow for enhanced patient outcomes, today announces the appointment of Richard F. Neville, MD, FACS and Mr Eric Chemla, FRCS to their Scientific Advisory Board.
Vascular Flow Technologies has two CE marked and FDA approved devices commercialised in Europe and the US, and has expanded the existing advisory board to develop the product pipeline, which is already supported by an impressive patent array.
Professor Neville is Chief of the Division of Vascular Surgery at George Washington University School of Medicine & Health Sciences, USA. His clinical interests include lower extremity revascularisation for peripheral arterial disease (PAD), wound healing and amputation prevention especially in diabetics, carotid treatment for stroke prevention including angioplasty and surgery, as well as hemodialysis access.
Professor Neville is a Distinguished Fellow of the Society for Vascular Surgery, a Fellow of the American College of Surgeons, and an active member of the Southern Association for Vascular Surgery, the Society for Clinical Vascular Surgery and the Eastern Vascular Society among others. Dr Neville is an international lecturer and publisher of over 60 manuscripts and 150 abstracts.
Mr Chemla is a Consultant Vascular Surgeon, a reader in vascular surgery and Divisional Chair of Cardiovascular Medicine at St George's Healthcare NHS Trust, UK. He specialises in complex vascular access for hemodialysis, and diabetic foot management. He was the UK representative on the board of the European Society for Vascular Access for 4 years and is an editor for the Journal of Vascular Access. Mr Chemla is also Visiting Professor at a number of US and European universities.
Bill Allan, CEO of Vascular Flow Technologies said: “We are honoured that Prof Neville and Mr Chemla have joined the Scientific Advisory Board. Their clinical experience and interests complement the existing SAB, and will strengthen market insight as we develop further applications for the SLF technology.”
Professor Richard Neville, Chief of the Division of Vascular Surgery at George Washington University School of Medicine & Health Sciences commented: “Spiral Laminar Flow is a relatively new technology which has already demonstrated improved outcomes in peripheral bypass and arteriovenous access graft. The technology also shows great promise in a number of other applications in vascular surgery, and I am extremely excited to be working to develop this innovative technology and the delivery of broader applications for a wider range of patients.”
Notes to Editors
About Vascular Flow Technologies
Vascular Flow Technologies is a leading innovator focused on the research, development and commercialisation of devices to improve blood flow in compromised or diseased blood vessels utilising its proprietary Spiral Laminar Flow™(SLF) technology. Natural blood flow has a distinctive singular spiral flow pattern and the patented SLF technology is the only clinically-proven design to replicate this.
VFT has two CE marked and FDA approved devices commercialised in Europe and the US, the Spiral Flow™ peripheral bypass (PV) graft and the Spiral Flow™ arteriovenous access (AV) graft. The SLF technology is used to create a longer lasting graft or stent, producing a better quality of life for the patient due to reduced vascular complications and improved longevity of the implant.
VFT is a privately held company with headquarters in Dundee, UK.
Further information is available at www.vascular-flow.com.
Issued for and on behalf of Vascular Flow Technologies by Instinctif Partners.
For more information please contact VFT@instinctif.com